We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $48.51, moving +0.81% from the previous trading session. This change lagged the S&P 500's 1.3% gain on the day. At the same time, the Dow added 1.41%, and the tech-heavy Nasdaq gained 1.75%.
Prior to today's trading, shares of the biopharmaceutical company had gained 4.07% over the past month. This has outpaced the Medical sector's loss of 1.21% and the S&P 500's gain of 0.46% in that time.
Investors will be hoping for strength from BMY as it approaches its next earnings release. In that report, analysts expect BMY to post earnings of $1.06 per share. This would mark a year-over-year decline of 2.75%. Our most recent consensus estimate is calling for quarterly revenue of $5.83 billion, up 2.36% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.28 per share and revenue of $24.07 billion. These totals would mark changes of +7.54% and +6.69%, respectively, from last year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.36% higher within the past month. BMY is currently a Zacks Rank #1 (Strong Buy).
Looking at its valuation, BMY is holding a Forward P/E ratio of 11.25. This valuation marks a discount compared to its industry's average Forward P/E of 14.1.
Meanwhile, BMY's PEG ratio is currently 2.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BMY's industry had an average PEG ratio of 2.04 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 27, putting it in the top 11% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $48.51, moving +0.81% from the previous trading session. This change lagged the S&P 500's 1.3% gain on the day. At the same time, the Dow added 1.41%, and the tech-heavy Nasdaq gained 1.75%.
Prior to today's trading, shares of the biopharmaceutical company had gained 4.07% over the past month. This has outpaced the Medical sector's loss of 1.21% and the S&P 500's gain of 0.46% in that time.
Investors will be hoping for strength from BMY as it approaches its next earnings release. In that report, analysts expect BMY to post earnings of $1.06 per share. This would mark a year-over-year decline of 2.75%. Our most recent consensus estimate is calling for quarterly revenue of $5.83 billion, up 2.36% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.28 per share and revenue of $24.07 billion. These totals would mark changes of +7.54% and +6.69%, respectively, from last year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.36% higher within the past month. BMY is currently a Zacks Rank #1 (Strong Buy).
Looking at its valuation, BMY is holding a Forward P/E ratio of 11.25. This valuation marks a discount compared to its industry's average Forward P/E of 14.1.
Meanwhile, BMY's PEG ratio is currently 2.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BMY's industry had an average PEG ratio of 2.04 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 27, putting it in the top 11% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.